Drug Trial Radar · NCT04234594
Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
Last checked: Nov 19, 2026Latest source record: May 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
94
Planned (sponsor's estimate)
Start
Oct 28, 2019
Primary completion
Sep 30, 2020
Study completion Sep 30, 2020
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind and parallel group study to compare the pharmacokinetic and safety of QL1203 and Vectibix® in healthy males.
Conditions
- Healthy Males
Interventions
QL1203Drug
6 mg/kg intravenous (IV) infusion only once,on the first day.
Vectibix®Drug
6 mg/kg intravenous (IV) infusion only once,on the first day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve (AUC0-t )Time frame: 36 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Guizhou Cancer Hospital
Guiyang, Guizhou, China · Recruiting
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.